On 29. Okt. 2025, GSK reported earnings of 0.55 USD per share (EPS) for Q3 25, beating the estimate of 0.48 USD, resulting in a 12.80% surprise. Revenue reached 8.55 milliarde, compared to an expected 8.57 milliarde, with a -0.28% difference. The market reacted with a +5.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 analysts forecast an EPS of 0.23 USD, with revenue projected to reach 8.70 milliarde USD, implying an decrease of -58.18% EPS, and increase of 1.78% in Revenue from the last quarter.
FAQ
What were GSK plc - ADR's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, GSK plc - ADR reported EPS of $0.55, beating estimates by 12.8%, and revenue of $8.55B, -0.28% below expectations.
How did the market react to GSK plc - ADR's Q3 2025 earnings?
The stock price moved up 5.1%, changed from $43.70 before the earnings release to $45.93 the day after.
When is GSK plc - ADR expected to report next?
The next earning report is scheduled for 04. Feb. 2026.
What are the forecasts for GSK plc - ADR's next earnings report?
Based on 9
analysts, GSK plc - ADR is expected to report EPS of $0.23 and revenue of $8.70B for Q4 2025.